Quale sarebbe il prezzo per ReNeuron Group plc (RENE)

Il prezzo per ReNeuron Group plc (RENE) è $0.00042815

Qual è la capitalizzazione di mercato per ReNeuron Group plc (RENE)

La capitalizzazione di mercato per ReNeuron Group plc (RENE) è $13.55K

ReNeuron Group plc (RENE) Prezzo e Capitalizzazione di Mercato

Established in 1997 and headquartered in Pencoed, UK, ReNeuron Group plc focuses on the research, development, and commercialization of innovative cell-based therapies. The company is actively developing a CTX stem cell therapy candidate targeting stroke disability, which is currently at the partnering stage for distribution both within and outside China. Another significant pipeline asset is its human retinal progenitor cell therapy, now in Phase I/IIa clinical trials, designed to treat retinitis pigmentosa, a debilitating eye disease leading to blindness. Furthermore, ReNeuron is conducting pre-clinical investigations into CTX-derived exosomes, which are microscopic, information-carrying packages released by CTX cells. The firm also generates revenue through the licensing of its ReNcell products. Collaboratively, ReNeuron has partnered with University College London to explore the creation of immune cells from induced pluripotent stem cells for application in anti-cancer cell therapies.

Il prezzo per RENE	Attivo B	Capitalizzazione del mercato a B	Risultati
$170,110 $13.55K	NVDA	$5.383T	+39,731,415,695.48%
$139,776 $13.55K	AAPL	$4.423T	+32,646,453,559.22%
$131,465 $13.55K	GOOG	$4.160T	+30,705,244,029.79%
$115,758 $13.55K	MSFT	$3.663T	+27,036,820,392.59%
$91,360.64 $13.55K	AMZN	$2.891T	+21,338,462,301.30%

Il prezzo per RENE

Attivo B

Capitalizzazione del mercato a B

Risultati

$170,110 $13.55K